Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence

Cancer

Volumn 86, Issue 2, 1999, Pages 316-324

  Miyake, Hideaki ^a,b   Hara, Isao ^a   Yamanaka, Kazuki ^a   Gohji, Kazuo ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Angiogenin; Prognosis; Recurrence; Urothelial carcinoma

Indexed keywords

ANGIOGENIN;

ANGIOGENESIS; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UROGENITAL TRACT CANCER;

ADULT; AGED; CARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTEIN BIOSYNTHESIS; PROTEINS; RIBONUCLEASE, PANCREATIC; TUMOR MARKERS, BIOLOGICAL; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 0033565399     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990715)86:2<316::AID-CNCR16>3.0.CO;2-T     Document Type: Article

References (24)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? N Engl J Med 1990;285:82-6.
2. Goldfarb M. The fibroblast growth factor family. Cell Growth Diff 1990;1:439-45.
3. Schrieber AB, Winkler ME, Derynck R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science 1986;232:1250-3.
4. Tisher E, Gospodarowicz D, Mitchell R, Silva M, Shilling J, Lau K, et al. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989;165:1198-206.
5. Ishikawa F, Miyazono K, Hellman U, Drexler H, Werustedt C, Hagiwara K, et al. Identification of angiogenic activity and the cloning and expression platelet-derived endothelial cell growth factor. Nature 1989;338:557-62.
6. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stage of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988;151:1312-8.
7. Fett JW, Strydom DJ, Lobb RR, Alderman EM, Lemuel Bethune J, Riordan JF, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 1985;24:5480-6.
8. Dickinson A, Fox S, Persad R, Hollyer J, Sibley G, Harris AL Quantitation of angiogenesis is an independent predictor of prognosis in invasive bladder cancer. Br J Urol 1994;74: 762-6.
9. Horak ER, Leek R, Klenk N, Le Jenue S, Smith K, Stuart N, et al. Angiogenesis assessed by platelet/endothelial cell adhesion molecule antibodies, as an indicator of node metastasis and survival in breast cancer. Lancet 1992;340:1120-4.
10. Rybak SM, Fett JW, Yao Q-Z, Vallee BL. Angiogenin mRNA in human tumor and normal cells. Biochem Biophys Res Commun 1987;146:1240-8.
11. Li D, Bell J, Brown A, Berry CL. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol 1994;172:171-5.
12. Shimoyama S, Gansauge F, Gansauge S, Negri G, Oohara T, Beger, HG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res 1996; 56:2703-6.
13. Olson KA, French TC, Vallee BL, Fett JW. A monoclonal antibody to human angiogenin suppress tumor growth in athymic mice. Cancer Res 1994;54:4576-9.
14. Olson KA, Fett JW, French TC, Key ME, Vallee BL. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 1995;92:442-6.
15. Gho YS, Lee JE, Oh KS, Bae DG, Chae C-B. Development of antiangiogenin peptide using a phage-displayed peptide library. Cancer Res 1997;57:3733-40.
16. Chopin DK, Caruelle JP, Colombel M, Palcy S, Raver V, Caruelle D, et al. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine. J Urol 1993;150:1126-30.
17. Nguyen M, Watanabe H, Budson A, Richie J, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients, J Natl Cancer Inst 1993;85:241-2.
18. Brown L, Berse B, Jackman R, Tognazzi K, Manseau E, Dvorak H, et al. Increased expression of vascular permeability factor (VEGF) and its receptor in kidney and bladder cancers. Am J Pathol 1993;143:1255-62.
19. Fleming ID, Cooper JS, Henson, DE, Mutter RVP, Kennedy BJ, Murphy GP, et al. Cancer staging manual. 5th edition. Philadelphia: Lippincott-Raven, 1997.
20. Miyake H, Yoshimura K, Hara I, Eto H, Arakawa S, Kamidono S. Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J Urol 1997;157:2351-5.
21. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers. Cancer Res 1996; 56:2515-8.
22. Mizutani Y, Okada Y, Yoshida O. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma. Cancer 1997;79:190-4.
23. Malkowicz SB, Nichols P, Lieskovsky G, Boyd SD, Huffman J, Skinner DG. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2). J Urol 1990;144:641-5.
24. Pagano F, Bassi P, Galetti TP, Meneghini A, Milani C, Artibani W. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 1991;145:45-50.